<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531165</url>
  </required_header>
  <id_info>
    <org_study_id>ESR14-10591</org_study_id>
    <nct_id>NCT02531165</nct_id>
  </id_info>
  <brief_title>Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</brief_title>
  <acronym>PERSEUS</acronym>
  <official_title>Comparison of Analgesia With Fentanyl and Morphine on Platelet Inhibition After Pre-hospital Ticagrelor Administration in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, open-label, single-center, investigator-initiated trial, including
      patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary
      percutaneous coronary intervention (PPCI) within 12 hours of the symptom's onset. The study
      aims to compare platelet inhibition (pharmacodynamics and pharmacokinetics) of pre-hospital
      Ticagrelor in patients with STEMI according to two different analgesia protocols using
      Fentanyl or Morphine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive patients with acute STEMI within 12 hours of the symptoms' onset and candidates
      for PPCI will be screened for inclusion in the study. Eligible patients who require analgesia
      for the relief of acute chest pain, defined as Visual Analogue Scale â‰¥3, will be randomized
      in a 1:1 ratio into one of the two treatment arms to receive analgesia with either Morphine
      or Fentanyl following administration of a pre-hospital loading dose of Ticagrelor. Randomized
      patients will undergo primary PCI and managed according to the current guidelines of the
      European Society of Cardiology. Blood samples (10 ml) will be collected at 0, 1, 2, 4, 6, 12
      and 24 hours after the loading dose of Ticagrelor to assess platelet inhibition using the
      VerifyNow P2Y12 function and the Vasodilator-Stimulated-phosphoprotein Phosphorylation (VASP)
      assays, plasma concentration of Ticagrelor and its active metabolite (AR-C124910XX) using a
      validated liquid chromatography/mass spectrometry detection method and the procoagulant
      action of platelets.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">February 6, 2018</completion_date>
  <primary_completion_date type="Actual">February 6, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Residual platelet reactivity (PR) by Platelet Reactivity Units (PRU)</measure>
    <time_frame>2 hours after loading dose of Ticagrelor</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual PR by PRU</measure>
    <time_frame>0, 1, 4, 6, 12 and 24 hours after the loading dose of Ticagrelor</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High on Treatment Platelet Reactivity (HTPR) rates</measure>
    <time_frame>0, 1, 2, 4, 6, 12 and 24 hours after the loading dose of Ticagrelor</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of Ticagrelor and AR-C124910XX</measure>
    <time_frame>at 1, 2, 4, 6 and 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak plasma concentration (tmax) of Ticagrelor and AR-C124910XX</measure>
    <time_frame>at 1, 2, 4, 6 and 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve of Ticagrelor</measure>
    <time_frame>at 1, 2, 4, 6 and 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with 70% or greater resolution of the ST-segment elevation before PCI</measure>
    <time_frame>at 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients without Thrombolysis in Myocardial Infarction flow grade 3 in the infarct-related artery at initial angiography</measure>
    <time_frame>at 2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-hospital Ticagrelor 180 mg loading dose orally.
Morphine, initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required.
Aspirin 500 mg loading dose orally (or intravenously).
Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT &gt;250 sec during PCI are allowed.
Primary PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-hospital Ticagrelor 180 mg loading dose orally.
Fentanyl, initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required.
Aspirin 500 mg loading dose orally (or intravenously).
Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT &gt;250 sec during PCI are allowed.
Primary PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).</description>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid</description>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_label>Fentanyl</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>500 mg loading dose orally (or intravenously), followed by 100 mg od</description>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractioned Heparin</intervention_name>
    <description>5'000 IU loading dose intravenously, additional doses to achieve an ACT &gt;250 sec during PCI are allowed.</description>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary PCI</intervention_name>
    <description>Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.</description>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18-year-old

          -  STEMI within 12 hours of symptoms' onset eligible for primary PCI with stent
             implantation.

          -  Patient able to give written informed consent.

        Exclusion Criteria:

          -  Contraindication, intolerance or hypersensitivity to Ticagrelor, or any excipients

          -  Contraindication, intolerance or hypersensitivity to Morphine, Fentanyl, or any
             excipients

          -  Active bleeding or bleeding diathesis

          -  History of intracranial haemorrhage

          -  Chronic oral anticoagulation treatment

          -  Previous antiplatelet treatment

          -  Contraindications to antiplatelet therapy

          -  Severe renal insufficiency (creatinine clearance &lt;30 mL/min)

          -  Severe hepatic dysfunction

          -  Severe chronic obstructive pulmonary disease

          -  Periprocedural glycoprotein IIb/IIIa inhibitors administration

          -  Relevant haematological disease

          -  Patient who is currently, plans, or has been enrolled in another clinical study
             involving use of an investigational drug or device within the prior 30 days.

          -  If female, patient pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan F. Iglesias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2015</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Dr Juan F. Iglesias, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

